[
  {
    "question": "Anti-Musk",
    "option_a": "Tongue weakness & Atrophy",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Anti-MuSK myasthenia gravis is a distinct subtype of myasthenia gravis where autoantibodies target muscle-specific kinase (MuSK), a protein essential for the maintenance and clustering of acetylcholine receptors at the neuromuscular junction. In Anti-MuSK MG, the autoantibodies disrupt the normal function of MuSK. This impairment results in defective clustering of acetylcholine receptors, leading to impaired neuromuscular transmission. The resulting dysfunction is particularly evident in bulbar muscles, often causing muscle weakness and atrophy, such as tongue atrophy. Clinically, patients present with prominent bulbar symptoms including dysarthria, dysphagia, and notably, tongue weakness and atrophy. These features help differentiate Anti-MuSK MG from the more common anti-AChR\u2010positive MG, where ocular symptoms might predominate. Diagnosis is achieved through a combination of clinical evaluation, electrophysiological studies (such as repetitive nerve stimulation and single-fiber EMG), and serum assays for anti-MuSK antibodies. Differential diagnoses include anti-AChR myasthenia gravis and motor neuron disease, which can be ruled out with appropriate antibody testing and EMG studies. First-line management generally includes immunosuppressive therapy, typically high-dose corticosteroids and steroid-sparing agents (e.g., azathioprine or mycophenolate mofetil). Acetylcholinesterase inhibitors are used but may be less effective than in AChR-positive MG. Plasmapheresis and IVIG are considered in acute exacerbations or severe presentations. For refractory cases, rituximab has shown promise. In pregnancy, corticosteroids are relatively safe with close monitoring, while other immunosuppressants require careful risk\u2013benefit analysis given potential teratogenic effects. During lactation, treatment choices must consider the potential transfer of medications to breast milk. Option A, 'Tongue weakness & Atrophy', is correct because it highlights the classic bulbar symptomatology associated with Anti-MuSK myasthenia gravis. Other potential options (not provided) would not capture this distinct clinical picture. \u2022 Anti-MuSK MG frequently presents with severe bulbar weakness and may mimic motor neuron disease due to muscle atrophy. \u2022 Tongue atrophy is a distinguishing physical finding in these patients. \u2022 Rituximab is an emerging therapy for refractory Anti-MuSK myasthenia. Recent research underscores the differential response of Anti-MuSK patients to conventional MG therapies, with studies supporting early use of rituximab in resistant cases. Current guidelines advocate for tailoring immunosuppressive therapies based on antibody status and clinical severity.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Dermatomyositis case",
    "option_a": "Perifascicular",
    "option_b": "Rimmed vacuoles",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Dermatomyositis is an idiopathic inflammatory myopathy characterized by both muscle weakness and distinctive cutaneous findings. A core pathological hallmark is the presence of perifascicular atrophy on muscle biopsy. The disease involves a complement-mediated microangiopathy that preferentially targets the capillaries supplying the muscle fibers at the periphery of the fascicles. This vascular compromise leads to ischemia and subsequent atrophy of these muscle fibers, resulting in a classic perifascicular pattern. Patients typically exhibit symmetric proximal muscle weakness along with characteristic skin manifestations such as heliotrope rash and Gottron\u2019s papules. The presence of perifascicular atrophy on biopsy strongly supports the diagnosis of dermatomyositis. Diagnosis involves a comprehensive evaluation including assessment of clinical features, measurement of muscle enzymes (e.g., CPK), electromyography, autoantibody screens (e.g., anti-Mi-2), and ultimately, a muscle biopsy showing perifascicular atrophy. Differential diagnoses include polymyositis (which lacks the skin findings) and inclusion body myositis, which is distinguished by the presence of rimmed vacuoles. The first-line treatment is high-dose corticosteroids, often followed by the addition of steroid-sparing immunosuppressive agents such as methotrexate or azathioprine. In refractory cases, IVIG or biologic therapies (e.g., rituximab) may be considered. During pregnancy, corticosteroids are typically the treatment of choice at the lowest effective dose due to their relatively favorable risk profile, whereas other immunosuppressants are generally avoided or used with caution. Similar considerations apply during lactation. Option A, 'Perifascicular', is correct as it accurately describes the classic biopsy finding in dermatomyositis. Option B, 'Rimmed vacuoles', is more indicative of inclusion body myositis, not dermatomyositis. \u2022 The combination of proximal muscle weakness and characteristic rash is pathognomonic for dermatomyositis. \u2022 Perifascicular atrophy on biopsy is a diagnostic cornerstone. \u2022 Early immunosuppressive treatment can reduce long-term morbidity. Recent guidelines emphasize early and aggressive immunosuppressive therapy to reduce irreversible muscle damage. Emerging research on biologics offers promising alternatives for patients who do not respond to conventional treatments.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Most common subtype of AchR antibody?",
    "option_a": "Binding",
    "option_b": "Modulating",
    "option_c": "Blocking",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "In myasthenia gravis, autoantibodies directed against acetylcholine receptors are central to the disease process. These antibodies can be subcategorized into binding, modulating, and blocking types, with the binding subtype being the most prevalent. Binding antibodies attach directly to acetylcholine receptors, leading to complement activation and receptor internalization. This results in a significant reduction in the number of available receptors, impairing neuromuscular transmission and producing the hallmark symptoms of myasthenia gravis. Patients with myasthenia gravis typically exhibit fluctuating muscle weakness, ptosis, diplopia, and other symptoms related to impaired neuromuscular transmission. The predominance of binding antibodies in the majority of patients explains their responsiveness to therapies that target the autoimmune process. Diagnosis is based on serological detection of anti-AChR antibodies (typically by radioimmunoassay), along with electrophysiological tests such as repetitive nerve stimulation and single-fiber EMG. Differentials include seronegative MG and other neuromuscular junction disorders like Lambert\u2013Eaton syndrome. Management involves symptomatic improvement with acetylcholinesterase inhibitors (e.g., pyridostigmine), and long-term immunosuppression with corticosteroids and other agents such as azathioprine or mycophenolate mofetil. Thymectomy is considered in select patients. For pregnant women, careful titration of medications (with steroids being the mainstay) is critical, while acetylcholinesterase inhibitors can be used with close monitoring. During lactation, the chosen medications should be evaluated for their safety profile based on current guidelines. Option A, 'Binding', is correct as it represents the most commonly observed type of anti-AChR antibody in myasthenia gravis. Options B (Modulating) and C (Blocking) are less common and do not represent the predominant subtype. \u2022 Approximately 80-85% of myasthenia gravis patients have detectable binding anti-AChR antibodies. \u2022 Complement-mediated receptor destruction is a primary mechanism of weakness in MG. \u2022 Management strategies are tailored to both clinical response and antibody profile. Latest studies continue to support the central role of binding antibodies in MG and underscore the importance of individualized immunosuppressive regimens. Consensus guidelines from neurology societies reinforce conventional treatment protocols with emerging support for biologic therapies in refractory cases.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "patient with hereditary peripheral neuropathy and transient CNS symptoms, what is the diagnosis",
    "option_a": "CMTX",
    "option_b": "CMT2",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Charcot-Marie-Tooth (CMT) disease is a group of hereditary motor and sensory neuropathies. Among its subtypes, CMTX (X-linked Charcot-Marie-Tooth) is notable for its association with transient central nervous system (CNS) symptoms in addition to peripheral neuropathy. CMTX is most commonly linked to mutations in the GJB1 gene, which encodes the gap junction protein connexin 32. Defects in this protein disrupt both peripheral nerve myelination and may also affect CNS white matter integrity, leading to transient neurological events. Patients typically present with features of peripheral neuropathy such as distal muscle weakness, foot deformities (like pes cavus), and sensory loss. In CMTX, the additional occurrence of transient CNS symptoms\u2014such as dysarthria, ataxia, or transient weakness\u2014helps distinguish it from other forms of CMT that primarily affect peripheral nerves. The diagnostic process includes a thorough clinical evaluation, nerve conduction studies, and confirmation via genetic testing for mutations in the GJB1 gene. Differential diagnoses include other forms of CMT (e.g., CMT1 or CMT2), which generally lack CNS manifestations, as well as other demyelinating disorders affecting the CNS. Management is largely supportive, focusing on physical therapy, orthotic devices, and sometimes surgical correction of deformities. There is no curative treatment. In pregnant patients, supportive measures remain the mainstay, with attention to mobility and pain management. Treatment modalities, primarily non-pharmacological, are generally safe during lactation. Option A, 'CMTX', is correct because it best describes a hereditary neuropathy that includes transient CNS symptoms. Option B, 'CMT2', is typically an axonal form of CMT that does not usually present with CNS involvement. \u2022 CMTX is the most common X-linked form of CMT and can include transient CNS events. \u2022 Genetic testing is pivotal for an accurate diagnosis. \u2022 Supportive therapy remains the cornerstone of management, as no disease-modifying treatment exists. Recent research into connexin 32 has expanded our understanding of the molecular mechanisms underlying CMTX. Although treatment remains supportive, there is ongoing investigation into potential gene-based therapies. Current guidelines continue to recommend multidisciplinary management focused on symptom relief and physical rehabilitation.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "L5 muscle in EMG testing",
    "option_a": "Tibialis anterior",
    "option_b": "Gastrocnemius",
    "option_c": "Gluteus medius",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The L5 nerve root is typically evaluated by testing muscles predominantly innervated by it. Tibialis anterior, which is essential for dorsiflexion of the foot, is classically used in electromyography (EMG) to asses L5 involvement. Any pathology affecting the L5 nerve root (such as radiculopathy or foraminal stenosis) often leads to denervation or impaired innervation of the tibialis anterior muscle. EMG helps by revealing abnormal spontaneous activity or recruitment patterns in muscles supplied by the affected root. L5 radiculopathy often presents with foot drop, gait disturbances, and sometimes lateral leg pain. Weakness in tibialis anterior manifests as difficulty in dorsiflexion, which is directly correlated with L5 nerve dysfunction. Evaluation includes a detailed neurophysiological examination (EMG/NCS) of muscles selectively innervated by specific roots. Differential diagnoses include S1 radiculopathy (typically affecting gastrocnemius) and L2-L4 involvement (affecting other hip and thigh muscles). Management is based on the underlying cause. Conservative treatment includes physical therapy, pain management, and sometimes epidural steroid injections. In cases of severe or refractory compression, surgical decompression may be indicated. In pregnant or lactating patients, conservative measures and physical therapy are preferred, with careful consideration regarding medications. Option A (Tibialis anterior) is correct because it is the most commonly tested L5-innervated muscle in EMG studies. Option B (Gastrocnemius) is more associated with the S1 nerve root, and Option C (Gluteus medius) is mainly linked to the L4/L5 roots but is not the classic muscle to assess for isolated L5 involvement. 1. Tibialis anterior weakness is a key indicator of L5 radiculopathy. 2. Foot drop is a hallmark clinical sign associated with L5 nerve involvement. 3. EMG testing helps in objectively localizing nerve dysfunction. Recent guidelines and neurophysiology consensus statements continue to support the use of tibialis anterior in EMG studies for L5 radiculopathy localization. Advances in imaging have complemented electrodiagnostic techniques in confirming the diagnosis.",
    "exam_year": "2023",
    "exam_type": "Part II",
    "image_url": "page_1.png"
  },
  {
    "question": "What is the cause of prolonged duration and drop amplitude in CMAP",
    "option_a": "Low temperature",
    "option_b": "Conduction block in some fibre",
    "option_c": "Temporal dispersion",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "The compound muscle action potential (CMAP) is an aggregate measure of the electrical activity of muscle fibers activated by nerve stimulation. Its characteristics, including amplitude and duration, provide insight into the underlying nerve conduction properties. Temporal dispersion occurs when there is a loss of synchrony among nerve fibers due to differential slowing of conduction velocities, usually caused by demyelination. The result is a broadening of the CMAP waveform (prolonged duration) accompanied by a reduction in peak amplitude due to phase cancellation of asynchronously conducting fibers. Temporal dispersion is a common finding in demyelinating neuropathies such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or multifocal demyelinating conditions. Clinically, patients may present with progressive weakness and reduced reflexes. Distinguishing between temporal dispersion and conduction block is essential. Conduction block results in an amplitude drop without significant change in duration, whereas temporal dispersion specifically causes a prolonged duration with a secondary drop in peak amplitude. Differential diagnoses include axonal neuropathies (which show reduced amplitude without prolongation) and temperature-related conduction slowing. Management of demyelinating neuropathies may involve immunomodulatory treatments such as corticosteroids, intravenous immunoglobulin (IVIG), or plasmapheresis. In pregnant or lactating patients, IVIG is often preferred given its safety profile, while corticosteroid use requires careful dosing and monitoring. Option C (Temporal dispersion) correctly explains the observation of both prolonged duration and a drop in amplitude. Option A (Low temperature) can slow nerve conduction but does not typically produce the characteristic waveform broadening seen with temporal dispersion. Option B (Conduction block) generally results in a marked drop in amplitude without the corresponding increase in duration. 1. A prolonged CMAP duration is the hallmark of temporal dispersion following demyelination. 2. Temporal dispersion implies desynchronized nerve fiber conduction. 3. Differentiating temporal dispersion from conduction block is critical for accurate electrophysiologic diagnosis. Current research supports temporal dispersion as a sensitive marker for demyelinating pathology within the nerve, with latest electrophysiologic criteria helping to distinguish it from conduction block in clinical practice.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Median nerve with NCS at elbow & wrist. what is?\n- conduction block\n- Dispersion",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "condu",
    "subspecialty": "Neuromuscular",
    "explanation": "In nerve conduction studies (NCS), evaluating the median nerve at the elbow and wrist is a common approach to identify focal demyelination or entrapment neuropathies. A significant drop in the compound muscle action potential (CMAP) amplitude when stimulating proximally compared to distally is indicative of conduction block. Conduction block is characterized by a failure of some nerve fibers to conduct action potentials across a specific segment of the nerve. This can be due to focal demyelination, inflammation, or compression, leading to a marked drop in amplitude when stimulation bypasses the lesion. Patients with conduction block in the median nerve may present with symptoms of carpal tunnel syndrome or other focal neuropathies, such as muscle weakness and sensory deficits in the nerve's distribution. In NCS, a significant amplitude drop when stimulating proximally (e.g., at the elbow) relative to distal sites (e.g., at the wrist) indicates conduction block. Temporal dispersion, a related but different phenomenon, would show a prolonged duration without a corresponding amplitude drop. Differential diagnoses include primarily axonal loss (uniform reduction in amplitude without conduction block) and demyelinating processes with temporal dispersion. Management depends on the underlying cause. For entrapment neuropathies, initial treatment is conservative, including splinting, activity modification, and NSAIDs. If symptoms persist, corticosteroid injections or surgical decompression may be considered. In pregnant or lactating patients, conservative therapies are preferred, and any invasive intervention should be carefully weighed against potential risks. The option 'Conduction block' is correct because it is specifically characterized by a significant amplitude reduction upon proximal stimulation, confirming a failure of impulse transmission over a nerve segment. 'Dispersion' is incorrect in this context since, although temporal dispersion may coexist with conduction block, it is defined by a broadened CMAP waveform rather than a primary amplitude drop. 1. A pronounced drop in CMAP amplitude from distal to proximal stimulation is the hallmark of conduction block. 2. Conduction block is more specific for focal demyelination than temporal dispersion. 3. Accurate differentiation between conduction block and temporal dispersion is essential in establishing the correct diagnosis. Recent electrophysiology guidelines reinforce the use of amplitude comparison between proximal and distal stimulation sites as a key diagnostic criterion for identifying conduction block in the median nerve, especially in entrapment syndromes and focal demyelinating neuropathies.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Parsonage-Turner",
    "option_a": "Upper brachial Plexus",
    "option_b": "Both the upper and lower plexus",
    "option_c": "Lower brachial",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Parsonage-Turner syndrome, also known as neuralgic amyotrophy, is a painful condition that primarily affects the brachial plexus. The classical presentation involves the upper brachial plexus, leading to acute onset shoulder pain followed by muscle weakness and atrophy. The syndrome is thought to be immune-mediated or post-infectious/inflammatory in nature, resulting in damage to the nerves of the upper brachial plexus. This leads to disruption of neural conduction and subsequent denervation of the affected muscles. Clinically, patients experience severe shoulder pain that often precedes motor deficits in the shoulder girdle, such as weakness in the deltoid, supraspinatus, or infraspinatus muscles. The distribution typically follows the upper trunk of the brachial plexus. Diagnosis is based on clinical history, physical examination, and supported by electrodiagnostic studies (EMG/NCS) which show denervation in the muscles supplied by the upper brachial plexus. Differential diagnoses include cervical radiculopathy and rotator cuff pathology, which can be differentiated by imaging and the distribution of weakness and pain. Management is primarily supportive, involving pain control (using NSAIDs or neuropathic pain agents), physiotherapy, and sometimes corticosteroids to reduce inflammation. In pregnant or lactating patients, non-pharmacologic pain management and physical therapy are particularly favored due to safety profiles. Corticosteroids, while sometimes useful, should be used with caution in these populations. Option A (Upper brachial plexus) is correct because Parsonage-Turner syndrome classically affects the upper trunk, leading to pain and motor deficits in shoulder-related muscles. Option B, suggesting the involvement of both upper and lower plexus, and Option C (Lower brachial) are less accurate representations of the usual clinical pattern. 1. Parsonage-Turner syndrome typically presents with sudden, severe shoulder pain followed by muscle weakness and atrophy in the upper plexus distribution. 2. Early conservative management with pain control and physical therapy can improve outcomes. 3. Awareness of this syndrome is crucial to avoid misdiagnosis as cervical radiculopathy or rotator cuff injury. Recent studies emphasize the immune-mediated aspect of Parsonage-Turner syndrome, with evolving evidence supporting early physical therapy and cautious use of corticosteroids. Consensus guidelines also reinforce conservative management, particularly in populations such as pregnant and lactating women.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "HCV & Neuropathy",
    "option_a": "Cryoglobulinemia",
    "option_b": "??",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Hepatitis C infection is well known for its extrahepatic manifestations. One important complication is mixed cryoglobulinemia, an immune-complex mediated vasculitis that commonly affects small vessels, including those supplying peripheral nerves, resulting in neuropathy. In HCV-related cryoglobulinemia, circulating cryoglobulins (immunoglobulins that precipitate at lower temperatures) deposit in small vessels, leading to complement activation and vasculitic injury. This inflammation can impair blood flow to nerves, causing ischemic injury and a sensorimotor neuropathy. Recent evidence reinforces that cryoglobulinemic vasculitis similarly targets renal and skin vessels, explaining the systemic nature of the disease. Patients with HCV-associated cryoglobulinemia may present with symptoms such as burning or tingling in the extremities, symmetrical sensorimotor deficits, and sometimes accompanying signs like palpable purpura, arthralgias, or renal involvement. The neuropathy is often of the vasculitic type with both sensory and motor involvement. Workup includes screening for HCV antibodies, detection of cryoglobulins in serum, complement levels (often low C4), and rheumatoid factor. Nerve conduction studies typically show a mixed pattern (axonal and demyelinating features). Differential diagnoses include diabetic neuropathy, other vasculitic neuropathies, or autoimmune conditions like Sj\u00f6gren\u2019s syndrome. A comprehensive clinical evaluation helps distinguish these entities. The primary treatment objective is to eradicate HCV using direct acting antiviral agents, which can lead to improvement in cryoglobulinemia. In severe or life\u2010threatening cases (with significant vasculitis or organ involvement), immunosuppressive therapies such as corticosteroids or rituximab may be added. In pregnant or lactating women, management should be cautious: many antivirals (and certainly ribavirin) are contraindicated due to teratogenicity; treatment plans should be individualized in consultation with hepatology and maternal\u2013fetal medicine experts. Option A (Cryoglobulinemia) is correct as it is the most classical association of HCV-related neuropathy. The other options, though not provided here, would likely refer to alternative causes of neuropathy not directly linked with HCV. 1. Remember that HCV-associated cryoglobulinemia can manifest with a systemic vasculitis affecting the skin, kidneys, and peripheral nerves. 2. Early recognition and treatment of HCV with appropriate antiviral therapy can improve neuropathic symptoms. 3. Always assess for multi-organ involvement in patients with suspected cryoglobulinemia. Recent guidelines emphasize prompt antiviral treatment using direct acting antiviral agents for HCV, which significantly reduces cryoglobulin production and improves clinical outcomes. Ongoing research continues to refine immunomodulatory regimens for patients with severe cryoglobulinemic vasculitis.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "HNPP case what is the gene",
    "option_a": "PMP22 duplication",
    "option_b": "PMP22 deletion",
    "option_c": "PM0",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) is an autosomal dominant disorder characterized by recurrent, focal pressure neuropathies. It results from a genetic defect affecting peripheral myelin integrity. HNPP is caused by a deletion in the peripheral myelin protein 22 (PMP22) gene located on chromosome 17p11.2. The reduced expression of PMP22 weakens the myelin sheath, making peripheral nerves particularly vulnerable to focal compressive injuries or entrapments. This distinguishes it from Charcot\u2013Marie\u2013Tooth disease type 1A (CMT1A), which results from PMP22 gene duplication. Clinically, patients present with transient episodes of numbness, muscle weakness, or paresthesias in the distribution of nerves susceptible to compression (e.g., ulnar neuropathy at the elbow, peroneal neuropathy at the fibular head). Attacks may be precipitated by minor trauma or prolonged pressure. Diagnosis involves electrodiagnostic studies that demonstrate focal slowing and sometimes conduction block at common entrapment sites. The definitive diagnosis is confirmed by genetic testing, which reveals a deletion in the PMP22 gene. Differential diagnoses include acquired entrapment neuropathies (like carpal tunnel syndrome) and other hereditary neuropathies such as CMT. Management is primarily supportive. Patients should be advised to avoid repetitive or prolonged pressure on vulnerable nerves, to use protective padding or splints when needed, and to engage in physical therapy. There is no curative treatment currently. In pregnancy and lactation, conservative management is preferred, with physical therapy and ergonomic advice being safe options. Option B (PMP22 deletion) is the correct answer. Option A (PMP22 duplication) is associated with CMT1A, not HNPP. Option C (PM0) appears to be a distractor and is not associated with this condition. 1. HNPP should be suspected in patients with recurrent, transient episodes of focal neuropathies, especially with a positive family history. 2. Distinguishing HNPP (PMP22 deletion) from CMT1A (PMP22 duplication) is critical because the clinical course and management strategies differ. 3. Early lifestyle modifications can help prevent nerve injury in HNPP. Recent genetic studies continue to validate the role of PMP22 deletion in HNPP. Current guidelines underscore conservative management and patient education, and genetic counseling is recommended for affected individuals and their families.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Exam for femoral nerve function",
    "option_a": "Hip flexion, knee extension & medial leg sensation",
    "option_b": "Hip lateral rotation, etc",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The femoral nerve supplies motor innervation primarily to the quadriceps muscle group (responsible for knee extension) and contributes to hip flexion via the iliopsoas. Its sensory branches, including the saphenous nerve, provide sensation to the anterior thigh and medial leg. Arising from the L2\u2013L4 nerve roots, the femoral nerve travels beneath the inguinal ligament and into the anterior thigh. Its injury or compression can impair both motor and sensory functions, leading to weakness and numbness in its distribution. Clinically, an exam assessing femoral nerve function involves testing knee extension strength (quadriceps function), hip flexion, and sensation on the medial aspect of the leg. Damage to the femoral nerve may cause difficulty in walking or standing up from a seated position along with sensory deficits. A detailed neurological exam is essential. Differential diagnoses may include an obturator nerve injury (which would more typically affect thigh adduction rather than knee extension) or lumbar plexus lesions. Confirmation can be obtained through nerve conduction studies and electromyography if needed. Treatment depends on the cause. For compressive or traumatic neuropathies, management includes physical therapy, analgesics, and in some cases, surgical decompression. In pregnant or lactating patients, conservative management is preferred with emphasis on physical therapy and pain control using medications that are safe in pregnancy. Option A is correct as it accurately describes the functions tested when assessing the femoral nerve: hip flexion (mainly via the iliopsoas), knee extension (quad strength), and medial leg sensation (via the saphenous branch). Option B mentioning hip lateral rotation is incorrect as this function is not mediated by the femoral nerve. 1. Always assess both motor and sensory components to fully evaluate nerve function. 2. The saphenous nerve, a branch of the femoral nerve, is a key indicator of medial leg sensation. 3. In cases of suspected femoral neuropathy, check for additional signs such as a diminished patellar reflex. Contemporary studies and clinical guidelines emphasize the importance of a thorough neurological exam to localize nerve lesions. Imaging and electrophysiologic studies have enhanced diagnostic accuracy in ambiguous cases.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Ulnar neuropathy, what will you find on day 5 in NCS",
    "option_a": "Decrease recruitment",
    "option_b": "Fibrillation",
    "option_c": "Complex repetitive discharges",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Ulnar neuropathy is a focal nerve injury often resulting from compression or trauma. Electrophysiologic studies (including both nerve conduction studies and needle electromyography) are crucial for assessing the functional status of the affected nerve. After an acute nerve injury, such as in ulnar neuropathy, Wallerian degeneration begins. However, the characteristic abnormal spontaneous activities (like fibrillation potentials) usually take 10\u201314 days to develop on needle EMG. Early changes, on around day 5, are more likely to manifest as decreased recruitment of motor units upon voluntary contraction, as the available motor units are reduced due to conduction block or early axonal loss. Patients with ulnar neuropathy typically present with weakness in the ulnar-innervated muscles of the hand (e.g., interossei and lumbricals) and sensory disturbances in the ulnar distribution of the hand. On early electrophysiologic testing, while overt spontaneous activity might be minimal, decreased recruitment during volitional activity indicates early denervation effects. The diagnosis is reached through a combination of clinical examination and serial electrophysiologic evaluations. Early on (around day 5), the absence of fibrillation potentials (which usually appear later) directs the examiner to look for decreased recruitment as an early marker. Differential diagnoses include other focal neuropathies (radial or median nerve) and early stages of generalized neuropathies. Initial management is conservative: avoiding exacerbating activities, splinting, and physical therapy are first-line approaches. In cases where conservative management fails or in severe neuropathy, surgical decompression may be indicated. In pregnancy and lactation, non-invasive approaches are preferred with careful consideration of medications for pain control. Option A (Decrease recruitment) is the most appropriate finding on day 5 following ulnar neuropathy. Option B (Fibrillation potentials) typically appear after 10\u201314 days, while Option C (Complex repetitive discharges) are associated with chronic reinnervation changes and not expected this early. 1. Denervation changes on EMG (such as fibrillations) have a delayed onset and may not be apparent until 10\u201314 days post-injury. 2. Early decreased recruitment on EMG is an important sign of compromised motor unit activation in acute neuropathy. 3. Serial electrophysiologic studies can help in tracking the progression or recovery of nerve injury. Recent research continues to validate the timeline of electrophysiologic changes post nerve injury. Updated guidelines recommend a combination of clinical and electrophysiologic monitoring to accurately assess nerve function and guide management decisions in acute peripheral neuropathies.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Case of AIDP with prior diarrhea 4 weeks ago, only motor with intact sensory.",
    "option_a": "AMAN",
    "option_b": "AMSAN",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Guillain-Barr\u00e9 syndrome (GBS) comprises several variants. The classic form, AIDP, generally presents with both motor and sensory deficits due to a demyelinating process. However, variants such as AMAN (acute motor axonal neuropathy) present with pure motor deficits and are frequently associated with antecedent gastrointestinal infections (e.g., Campylobacter jejuni). This case, featuring motor weakness with intact sensation following diarrhea, aligns best with the AMAN variant. In AMAN, an immune-mediated process, often post-infectious via molecular mimicry, leads to selective damage to motor axons while sparing sensory fibers. Autoantibodies target gangliosides on the motor nerve membrane, which distinguishes its pathophysiology from the demyelinating process seen in AIDP. The clinical picture of recent diarrhea (a common precursor to Campylobacter infection) followed by predominantly motor deficits (without sensory involvement) is highly suggestive of AMAN. In contrast, the AMSAN variant would also affect sensory fibers, and the classic AIDP typically shows both motor and sensory impairments. Differentiation among GBS subtypes is achieved via nerve conduction studies. In AMAN, studies typically show reduced compound muscle action potential amplitudes (indicative of axonal degeneration) with relatively preserved conduction velocities, as opposed to the demyelinating features of AIDP. CSF analysis demonstrating albuminocytologic dissociation further supports the diagnosis. Treatment for GBS\u2014including its AMAN variant\u2014primarily involves immunomodulatory therapies such as intravenous immunoglobulin (IVIG) or plasmapheresis. For patients who are pregnant or lactating, IVIG is generally preferred due to its favorable safety profile. Supportive management with respiratory monitoring is also essential. Option A (AMAN) is the correct answer because it corresponds to the clinical scenario of a post-diarrheal, pure motor variant of GBS. Option B (AMSAN) would include sensory deficits, which are not present here. With options C and D missing, the provided choices point clearly to AMAN. A preceding gastrointestinal infection is a common trigger for AMAN. The hallmark of AMAN is the selective involvement of motor nerves, making clinical history and electrophysiological studies crucial for accurate diagnosis. Recognizing the variant is important as it may influence both prognosis and management strategies. Recent guidelines and research underscore the importance of early use of IVIG in GBS management, including in the AMAN subtype. Safety profiles during pregnancy and lactation have been well established for IVIG, supporting its use over plasmapheresis in these populations.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "How to differentiate between conus medularis and cauda equina syndrome",
    "option_a": "Upper and lower neuron sign",
    "option_b": "Loss of reflexes",
    "option_c": "Loss of sphincter control",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This question requires distinguishing between conus medullaris syndrome and cauda equina syndrome. The pivotal differentiator is that conus medullaris syndrome, resulting from an injury at the terminal spinal cord, presents with a mix of upper motor neuron (UMN) and lower motor neuron (LMN) signs, whereas cauda equina syndrome involves damage to peripheral nerve roots and exhibits purely LMN features. Conus medullaris syndrome occurs due to lesions at the conus (T12\u2013L1 level) where both central (UMN) and peripheral (LMN) structures are affected, leading to mixed presentations. In contrast, cauda equina syndrome is caused by compressive or inflammatory injuries to the nerve roots below the conus, resulting in LMN deficits such as flaccid paralysis and absent reflexes. Patients with conus medullaris syndrome often present with acute bilateral lower extremity weakness, a mixed picture of spasticity alongside possible flaccidity, and early onset of bladder and bowel dysfunction. Cauda equina syndrome typically causes severe radicular pain, asymmetric lower limb involvement, areflexia, and later-onset sphincter dysfunction. The clinical exam should differentiate UMN signs (e.g., hyperreflexia, spasticity) seen in conus medullaris syndrome from the LMN features (e.g., hyporeflexia or areflexia, flaccidity) of cauda equina syndrome. MRI of the lumbosacral spine is key for localization. In pregnancy, MRI without contrast is generally safe and is the modality of choice; similar imaging considerations apply during lactation. Both syndromes require urgent evaluation with spinal imaging and, typically, prompt surgical decompression. For pregnant patients, MRI without contrast is indicated. In lactating women, MRI is also safe. Early surgical intervention helps to preserve neurologic function and prevent permanent deficits. Option A correctly highlights the mixed UMN and LMN signs associated with conus medullaris syndrome, making it the most reliable differentiator. Option B (loss of reflexes) is more typical for cauda equina syndrome. Option C (loss of sphincter control) can occur in both syndromes, reducing its specificity. Option D is not provided. When evaluating a patient with lower back and radicular symptoms, the presence of both UMN signs (e.g., hyperreflexia, spasticity) and LMN signs in the lower extremities strongly points to conus medullaris syndrome. In contrast, pure LMN findings such as diminished reflexes suggest cauda equina syndrome. Early diagnosis and treatment are crucial. Recent guidelines emphasize the importance of MRI in promptly distinguishing these syndromes to allow for timely surgical decompression. Research supports the fact that early intervention markedly improves outcomes and reduces the risk of permanent deficits, with particular caution advised in pregnant and lactating patients to use non-contrast imaging modalities.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Congenital Myasthenia gravis",
    "option_a": "Slow channel",
    "option_b": "Fast Channel",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Congenital myasthenic syndromes (CMS) are a group of inherited disorders affecting neuromuscular transmission. Unlike autoimmune myasthenia gravis, CMS are non\u2010immune and result from genetic defects affecting either the presynaptic, synaptic, or postsynaptic components of the neuromuscular junction. The slow-channel congenital myasthenic syndrome (SCCMS) is a recognized subtype characterized by prolonged opening of the acetylcholine receptor (AChR) channel. In slow-channel CMS, point mutations (commonly in one of the AChR subunit genes such as CHRNA1, CHRNB1, CHRND, or CHRNE) result in a prolonged opening of the postsynaptic AChR channels after the binding of acetylcholine. This prolonged channel opening leads to excessive cation (especially Ca2+) influx, which in turn results in endplate myopathy with structural damage to the postsynaptic membrane. Patients with slow-channel CMS typically present in infancy or early childhood with fatigable skeletal muscle weakness, often accompanied by ocular symptoms like ptosis and ophthalmoparesis. The clinical picture may overlap with autoimmune myasthenia gravis, but the early age at onset, a positive family history, and the absence of circulating autoantibodies help differentiate CMS from its autoimmune counterpart. The diagnostic workup involves a detailed clinical history and physical examination with emphasis on early childhood onset and family history. Electrophysiological studies, such as repetitive nerve stimulation and single-fiber electromyography, typically reveal a decremental response. Genetic testing confirms the diagnosis by identifying mutations in the genes encoding the AChR subunits. Differential diagnoses to consider include autoimmune myasthenia gravis, other myopathies, and metabolic disorders affecting muscle function. Management is guided by the underlying genetic mechanism. For slow-channel CMS, therapies aimed at reducing the excessive and prolonged receptor activation are preferred. Agents such as open-channel blockers (e.g., quinidine or fluoxetine) may be used to normalize the excessive channel opening. It is critical to note that cholinesterase inhibitors, commonly used in autoimmune myasthenia gravis, may worsen symptoms in slow-channel CMS by further increasing acetylcholine concentration and prolonging receptor activation. In pregnant or lactating women, any potential medication (including quinidine or other channel blockers) should be carefully evaluated for teratogenicity and effects on the infant, with treatment decisions made using the most up-to-date guidelines and risk-benefit analysis. The options provided include 'Slow channel' (Option A) and 'Fast channel' (Option B), with Options C and D left blank. 'Slow channel' refers to the slow-channel congenital myasthenic syndrome, which is a well-recognized subtype of CMS. The marked answer, Option A, is thus consistent with the established categorization of congenital myasthenic disorders. \u2022 Distinguish CMS from autoimmune myasthenia gravis by noting the early age of onset and absence of autoantibodies.  \u2022 In slow-channel CMS, cholinesterase inhibitors may exacerbate symptoms, thus highlighting the need for tailored therapy.  \u2022 Accurate genetic testing is essential for confirming the diagnosis and guiding treatment.  \u2022 Always consider the safety profile of proposed treatments in pregnant or lactating patients. Recent advances highlight the importance of genetic confirmation in congenital myasthenic syndromes, with studies demonstrating specific mutations in AChR subunits underlying slow-channel CMS. Emerging therapies focus on modulating receptor kinetics, and current clinical guidelines underscore the need for individualized treatment, especially in special populations such as pregnant and lactating women, where drug safety profiles must be rigorously assessed.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "A scenario about pt with shoulder and arm pain w MRI spine showed disc prolapse at the level of C5 what is the muscle to be examined by EMG?",
    "option_a": "Infraspinatus",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Cervical radiculopathy results from nerve root compression due to a disc prolapse. In a lesion at the C5 level, the nerve root provides motor innervation to several shoulder muscles, including the deltoid, supraspinatus, and infraspinatus. EMG examination targets muscles with predominant innervation by the affected root to confirm denervation and help localize the lesion. A disc prolapse at the C5 level compresses the C5 nerve root, impairing its function. This compression disrupts both motor and sensory fibers, leading to potential weakness, pain, and sensory deficits in structures innervated by C5. The infraspinatus muscle, which is primarily innervated by the suprascapular nerve with fibers from C5 (and partly C6), can manifest denervation changes detectable on EMG. Patients with a C5 radiculopathy may present with shoulder and lateral arm pain, weakness in shoulder abduction and external rotation, and sometimes sensory changes over the lateral aspect of the arm. Evaluating the infraspinatus is particularly useful because its selective innervation makes it an effective marker for confirming a C5 radiculopathy via EMG. Diagnosis of cervical radiculopathy is based on clinical history, physical examination (assessing muscle strength, reflexes, and sensory deficits), and imaging studies such as MRI, which in this case confirmed a disc prolapse at the C5 level. Electromyography is then utilized to examine muscles like the infraspinatus to detect signs of denervation and support the diagnosis. Management of cervical radiculopathy initially involves conservative measures including physical therapy, analgesics (such as acetaminophen or certain NSAIDs\u2014with caution in pregnancy and lactation), and a short course of oral corticosteroids if indicated. In pregnant or lactating patients, non-pharmacologic approaches and medications with established safety profiles (e.g., acetaminophen) are preferred. Interventional procedures like epidural steroid injections or surgical decompression are reserved for severe or refractory cases, with careful risk\u2010benefit discussions in special populations. Though multiple muscles can be evaluated in suspected C5 radiculopathy (e.g., deltoid, biceps), the infraspinatus is an optimal target for EMG testing. Its isolated innervation by fibers from C5 (and partly C6) and its role in external shoulder rotation make it sensitive to denervation changes secondary to C5 nerve root compression. When evaluating cervical radiculopathy by EMG, targeting a muscle with discrete innervation from the affected root (such as the infraspinatus for C5 lesions) increases diagnostic yield. Always correlate EMG findings with clinical presentation and imaging studies to arrive at an accurate diagnosis. Recent literature supports the use of EMG to confirm cervical radiculopathy by examining muscles with isolated innervation from the compressed nerve root. Evidence indicates that the infraspinatus muscle is a reliable muscle for demonstrating denervation changes in cases of C5 radiculopathy, and conservative management remains first-line therapy consistent with current neurology guidelines.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "ALS-FTD pathology",
    "option_a": "TDP43",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "ALS (Amyotrophic Lateral Sclerosis) and FTD (Frontotemporal Dementia) can occur in the same spectrum. A major neuropathological hallmark in these cases is the accumulation of TDP-43 protein. This protein, normally located in the nucleus, mislocalizes and aggregates in the cytoplasm in most cases of ALS and many cases of FTD. TDP-43 (TAR DNA-binding Protein 43) is involved in RNA metabolism. In ALS-FTD, abnormal post-translational modifications lead to its misfolding, cytoplasmic aggregation, and formation of ubiquitinated inclusions. This disrupts normal neuronal function and ultimately results in neurodegeneration. Recent studies continue to elucidate how these aggregates contribute to cell toxicity and spread. Clinically, patients with ALS present with both upper and lower motor neuron findings while those with FTD exhibit marked changes in behavior, personality, and executive function. The presence of TDP-43 protein inclusions correlates with disease progression and severity in both conditions. Diagnosis of ALS-FTD is primarily clinical \u2013 supported by electromyography, neuroimaging, and neuropsychological evaluation. Differential diagnoses include primary lateral sclerosis, progressive muscular atrophy, and other dementias. Neuropathologic confirmation (e.g., postmortem immunostaining for TDP-43) solidifies the diagnosis. Current management is supportive, with Riluzole and Edaravone being approved for ALS. Management of FTD includes behavioral interventions and, in some cases, symptomatic pharmacologic treatments. In pregnancy or lactation, medication risks must be weighed carefully; Riluzole is generally contraindicated during pregnancy, so multidisciplinary planning is essential. Option A (TDP-43) is correct because TDP-43 inclusions are the classic neuropathological finding in ALS-FTD. Other options (not listed) might have included proteins like FUS or SOD1; however, TDP-43 is by far the most common in this combined spectrum. 1) Approximately 97% of ALS cases show TDP-43 pathology. 2) ALS and FTD are clinically heterogeneous and can present with overlapping features. 3) Posttranslational modifications and aggregation of TDP-43 are critical to disease pathogenesis. Recent research emphasizes the role of TDP-43 in disrupting RNA processing and protein homeostasis. Advances in molecular genetics have improved our understanding of familial cases, and ongoing trials are investigating targeted therapies that might one day modify TDP-43 pathology.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with weakness provoked by excercise but then get better shortly.",
    "option_a": "Mylophposoprylase diffency",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The question describes a patient with exercise\u2010induced weakness that improves shortly after stopping the exercise. This is typical of metabolic myopathies, particularly McArdle disease, which is due to myophosphorylase deficiency. Myophosphorylase is an enzyme essential for glycogenolysis in skeletal muscle. In its deficiency (McArdle disease, or Glycogen Storage Disease type V), patients cannot break down glycogen efficiently to provide energy during high-intensity exercise. The resulting energy deficit leads to muscle cramps and weakness, and the phenomenon of improvement (often described as the 'second wind') occurs when muscles switch to using blood-borne fuels like free fatty acids and glucose. Clinically, patients present with exercise intolerance, cramps, and myalgia. They often notice a 'second wind' \u2013 an improvement in symptoms after a short period of rest \u2013 which is characteristic for McArdle disease. Diagnosis usually involves an ischemic forearm exercise test (demonstrating a failure of lactate production), measurement of creatine kinase levels, and genetic testing. Differentials include other metabolic myopathies such as myoadenylate deaminase deficiency and phosphofructokinase deficiency, which have distinct biochemical profiles. The mainstay of management is lifestyle adjustment \u2013 patients are advised to perform moderate aerobic exercise and to avoid strenuous activities. Dietary modifications, such as consuming carbohydrate-rich meals before exercise, can help. In pregnancy and lactation, careful activity planning is necessary to prevent symptomatic episodes; consultation with a metabolic specialist is recommended to adjust nutritional intake and exercise routines accordingly. Option A (Myophosphorylase deficiency) is correct because it directly indicates the enzyme deficiency underlying McArdle disease. Other options (though not listed) would not account for the distinctive 'second wind' phenomenon seen in this condition. 1) The \u2018second wind\u2019 phenomenon is a hallmark of McArdle disease. 2) Exercise intolerance in this disorder is due to an energy supply deficit from impaired glycogen breakdown. 3) Mild constant exercise with proper nutritional support can improve quality of life. Recent studies have focused on the potential benefits of tailored exercise regimens and dietary modifications. There is ongoing research into gene therapy approaches, although current management remains largely supportive.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with upper extremities painfulneuropsthy and atrophy how to treat",
    "option_a": "caspo ?? Cream",
    "option_b": "Deluxitine",
    "option_c": "ASM ? VPA",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "The question deals with the management of a patient presenting with upper extremity neuropathic pain accompanied by muscle atrophy. Neuropathic pain arises from injury or dysfunction of the nervous system and is commonly treated with medications that modulate pain pathways. Neuropathic pain is characterized by abnormal processing of pain signals due to nerve injury or dysfunction. Altered neurotransmitter signaling, especially involving serotonin and norepinephrine, plays a key role. Duloxetine, an SNRI, works by enhancing these inhibitory pain pathways, thereby reducing neuropathic pain symptoms. Patients with neuropathic pain often describe burning, tingling, or electric shock-like sensations. When associated with atrophy (suggesting some degree of ongoing denervation), the management focuses on alleviating pain and preserving function. Such scenarios might be seen in diabetic neuropathy or other focal neuropathies affecting the upper extremities. Evaluation should include a detailed history and neurological examination, supplemented by nerve conduction studies and electromyography if needed. Differentials include conditions like diabetic neuropathy, radiculopathy, entrapment neuropathies, and less commonly motor neuron diseases. The presence of atrophy suggests a chronic or severe process requiring a thorough workup. First-line treatments for neuropathic pain include SNRIs (such as duloxetine), gabapentinoids (gabapentin, pregabalin), and tricyclic antidepressants. Duloxetine (represented here as 'Deluxitine') is supported by evidence for reducing neuropathic pain symptoms. In pregnant patients, the use of duloxetine should be limited to cases where benefits outweigh risks (it is generally considered Category C, meaning risk cannot be ruled out), and caution is advised during lactation due to potential exposure via breast milk. Second-line treatments may include topical agents like capsaicin cream for localized pain, although they can be less effective in cases with significant atrophy. Option A (capsaicin cream) might offer localized symptom relief but is less effective for more generalized or severe neuropathic pain with atrophy. Option B (Deluxitine, interpreted as duloxetine) is correct as it is a well-established systemic therapy for neuropathic pain. Option C (ASM ? VPA, referring to valproic acid) is not a standard treatment for neuropathic pain. Thus, Option B is the best answer. 1) Duloxetine is a first-line agent for several neuropathic pain conditions. 2) Neuropathic pain treatment should be individualized, especially in the setting of motor atrophy. 3) Always consider the balance of efficacy and side effects, particularly in women who are pregnant or lactating. Recent guidelines and meta-analyses support the use of SNRIs like duloxetine as a first-line treatment for neuropathic pain, including diabetic peripheral neuropathy. Continued research is refining dosing strategies and long-term management, with particular attention to quality of life improvements and side-effect profiles.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Strachen Syndrome Case scenario of Vitamin E deficiency",
    "option_a": "Vitamine D",
    "option_b": "Vitamine E",
    "option_c": "Vitamine A",
    "option_d": "Vitamine B12",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Strachan Syndrome in this context is interpreted as a case scenario related to vitamin E deficiency. Vitamin E is a potent antioxidant essential for neuronal protection, and its deficiency is known to produce neurological symptoms resembling spinocerebellar ataxia. Vitamin E deficiency leads to increased oxidative stress and subsequent neuronal damage, particularly affecting the cerebellum and peripheral nerves. The resulting dysfunction can manifest as ataxia, peripheral neuropathy, and even retinopathy. The clinical picture is similar to that seen in conditions such as Friedreich ataxia, and early recognition is key to preventing progression. Patients typically present with progressive ataxia, dysarthria, and neuropathy. Affected individuals may have a history of fat malabsorption or genetic disorders affecting vitamin E metabolism. Correct identification of vitamin E deficiency is crucial since supplementation can improve or stabilize neurologic function if initiated early. Diagnosis is based on clinical presentation supported by laboratory measurements of vitamin E levels. Differential diagnoses include Friedreich ataxia and other inherited ataxias. Biochemical assays help differentiate pure vitamin E deficiency (which is treatable) from similar neurodegenerative disorders. The primary management is high-dose vitamin E supplementation. Early treatment can halt progression and sometimes improve symptoms. In pregnancy and lactation, vitamin E is considered safe; however, dosage should be monitored to avoid potential coagulopathy issues, especially in patients on concurrent anticoagulant therapy. Nutritional assessment and management of any underlying malabsorption are also important. Option A (Vitamin D), Option C (Vitamin A), and Option D (Vitamin B12) are incorrect because they do not address the specific oxidative and neuroprotective role of vitamin E. Only Option B (Vitamin E) is appropriate to correct the deficiency and its neurological manifestations. 1) Ataxia with Vitamin E Deficiency (AVED) can closely mimic Friedreich ataxia, making accurate diagnosis essential. 2) Early vitamin E supplementation can alter the disease course, underscoring the need for prompt recognition. 3) Always evaluate for fat malabsorption conditions in patients with vitamin E deficiency. Recent studies emphasize the importance of early detection of vitamin E deficiency and the benefits of supplementation in halting neurological deterioration. Updated guidelines support vitamin E therapy in patients with AVED, with ongoing research assessing optimal dosing and long-term outcomes.",
    "exam_year": "2023",
    "exam_type": "Part II"
  }
]